The last time AI supercharged a sector, here’s what happened…

Dear Reader,

Happy Friday!

I’m excited it’s Friday…

Excited about the drug business, excited about the webinar we just went live with yesterday.

OFFICIAL REPLAY NOW STREAMING

$width=573 height=323 /></a> Ex-Wall Street CEO Dylan Jovine has only made 3 all-in calls in the past 20 years…2009: Dylan went live on Fox Business and called the bottom on the financial crisis almost to the day. His recommendations that day climbed 1,300% and 2,056%.2020: He called the bottom of the Covid crash and told his readers to go “all-in” on tech. Rocket Lab surged 1,700%. Axon skyrocketed 2,725%.2022: He predicted Russia was about to invade Ukraine. He knew what would happen next and told readers to go “all-in” on defense stocks. Palantir exploded 2,800%.He just did it again.And just like before, he's calling a bottom on a class of stocks poised to soar 1,000% or more for investors who place their trades BEFORE October 29th.<a href=https://www.behindthemarkets-btm.com/4MZ2NG/MPWX6H/?sub2={$email}&sub1=102425ddad target=_blank rel=noopener>Click here to catch the replay >>></a>See, <a href=http://youtube.com/watch?v=DqaafxE4c1A&feature=youtu.be target=_blank rel=noopener>a few massive things are happening here</a> -Biotech is the cheapest sector in the S&P 500…Biotech has an inverse relationship to interest rates - meaning, when interest rates go down, biotech stock prices go up, and biotech stock takeovers go bananas…We have Trump’s Big Beautiful Bill protecting certain biotech companies from Medicare price controls and from competition…And we have AI slashing costs and speeding up drug discovery - something I haven’t talked enough about this week.But AI’s role in biotech is very exciting, and we are watching it unfold in real time.It’s fascinating - you know, there’s almost 10,000 “rare” diseases out there, and we only have treatments for about 5% of them.There’s a lot of work to do.One reason there’s so little treatment available is because it’s so intense to get a drug from inception to approval.On average, it takes about 10 years and costs $3 billion.So the question has always been, how do you lower that time horizon and cost?In the nineties, Wall Street was mad at Big Pharma…They did all this drug development, and the success rate was low.Wall Street said, “get these R&D departments out of your company.”That created the biotech industry we know today.Wall Street forced big pharma companies like Lilly and Glaxo and Merck to shrink their R&D budgets to get higher returns on investment.That created a lot of little independent biotech companies.Now, all these companies are starting to use AI to help them understand the chemistry of what works.What’s really interesting, too, is that RFK Jr’s HHS and FDA are pushing these companies to use AI in their clinical trial cycles to speed up the drug discovery and approval processes.This was done by executive order a few months back.Now, any time you speed something up in business, you automatically lower your cost. It’s the mantra, faster, better, cheaper.AI is helping these biotech stocks make their drug discovery process faster, better, cheaper.This means we can now use AI to help speed up that process so that instead of treating 5% of rare diseases, we’ll be able to treat a lot more and with a lot lower investment.A lower investment means a much higher return.So for a lot of reasons there’s this massive setup right now in the drug discovery and pharmaceutical sector that most people aren’t seeing.They’re focused on the headlines - Trump-bashing, lower prices on Ozempic, or drugs that have been in the game for a long time.But under the surface there is a lot going right for biotech innovators…It’s set up the kind of opportunity that only comes around once in a while - in fact, this is only the fourth time in 20 years I’m going on record to make an “all-in” call <a href=https://www.behindthemarkets-btm.com/4MZ2NG/MPWX6H/?sub2={$email}&sub1=102425dded target=_blank rel=noopener>like this one</a>.And it’s why we are already seeing the “smart money” running back into biotech, ahead of the Fed’s October 29th announcement.There’s still time to get in before the mainstream, but the window is closing fast. By next week, the biggest gains may be off the table.This really reminds me of the setup we had for AI in defense…When we said to ourselves, “everyone is talking about how AI will change the workplace. But how will AI change warfare?”I started recommending companies like AeroVironment… Kratos… and Palantir at just $7.These companies all delivered triple-digit gains for our readers, and Palantir has run up 2,800% since our recommendation.That’s the kind of opportunity I see today in biotech.Just like defense before the Ukraine war, biotech is in a “forgotten” sector…And just like I predicted in advance Russia would bring the world into a new cycle of war, triggering a massive opportunity in defense stocks, and positioned readers for the gains that followed…I now see not one, but THREE mega catalysts converging that will bring biotech back into the spotlight.And send <a href=https://www.behindthemarkets-btm.com/4MZ2NG/MPWX6H/?sub2={$email}&sub1=102425dded target=_blank rel=noopener>these three stocks </a>soaring up to 1,000% each.But the deadline to get in is just days from now.Today is the last day to get in position before the market closes for the weekend.Don’t sleep on this opportunity. I believe you WILL regret it.<a href=https://www.behindthemarkets-btm.com/4MZ2NG/MPWX6H/?sub2={$email}&sub1=102425dded target=_blank rel=noopener>Go here now to see the replay before it’s offline>>></a>“The Buck Stops Here,”<div data-below-article-slot class=$

The last time AI supercharged a sector, here’s what happened…

Discover Great Companies Trading at a Discount

Trump just opened this profit window…

The best thing that happened last week